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GENERAL INTRODUCTION
      Cancer is a serious medical and social problem throughout the world.
In recent years in Japan, the number of cancer patients and cancer deaths has
increased steadily and became the top ofcause of death in 1981. According to
statistics complied by the Ministry of Health, Labor and Welfare, 344,105
people died of cancer in 2010. The major cause of cancer death among
Japanese since 1993 has been lung cancer, followed by stomach and colon
cancer. Conspicuous medical progress has led to some kinds ofcancers being
cured routinely. However, traditional medical approaches to cancer treatment
have generally focused on cancers that occur in large numbers of affected
indiViduals. Others cancers, particularly those that occur in small numbers of
patients, often remain lacking in effective medical treatments. Therefore,
research approaches toward rare cancers are very important from a social and
medical viewpoint. Furthermore, efforts to generate therapies for rare cancers
might clarify new viewpoints and provide insight into the treatment of
common cancers.
      Medullary thyroid carcinoma (MTC) is a rare endocrine tumor
comprising a malignant neoplasm of calcitonin-secreting C cells of the
thyroid gland and represents approximately 3-50/o of all thyroid cancers.(i)
MTC occurs in a sporadic form in about 750/o of cases, and the remaining 250/o
are three familial forms; multiple endocrine neoplasia type IIA (MEN2A),
multiple endocrine neoplasia type IIB (MEN2B), and familial MTC not
associated with MEN (FMTC).(2) The only effective treatment for MTC is
surgical removal of the neoplastic tissue with central lymph node
dissection.(3) In the case of total thyroidectomy, however, lifelong hormone
replacement therapy is necessary for patients, which decreases their quality
of life. Most chemotherapy or radiotherapy for MTC has shown inconclusive
results. The lack of effective systemic therapy for MTC shows the importance
ofdeveloping new approaches for the treatment ofthis cancer. Vandetanib, an
epidermal growth factor receptor-tyrosine kinase inhibitor, was approved by
the FDA in April 2011 for the treatment of symptomatic progressive MTC in
patients with unresectable (non-operable) locally advanced or metastatic
disease.(4) Thus, this positive approach for the treatment of MTC is attracting
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significant attention.
      Recently, therapeutic approaches for MTC using irinotecan (CPT-11,
Fig. 1) have been reported in animal experiment.(5)'(6) CPT-11 is a
water-soluble derivative prodrug of camptothecin and is converted to
7-ethyl-10-hydroxy-camptothecin (SN-38, Fig. 1), the active metabolite of
CPT-11, by carboxyl esterase.(7)'(8) CPT-11 inhibits the resealing of
single-strand DNA breaks mediated by topoisomerase I by stabilizing
cleavable complexes and is a cell-cycle-specific drug. (9'ii) Based on this, a
long period of exposure to CPT-11 mediates a reduction in tumor cells, but
treatment with CPT-11 is limited because of its short half-life and serious
side-effects, such as bone-marrow suppression.(i2) Success in the treatment of
MTC with CPT-11 requires selective delivery to tumor tissues and limited
distribution to normal tissues.
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      Drug delivery systems (DDSs) such as micelles,(i3) microparticles(i4)
and liposomes(i5)'(i6) have been investigated to increase selective drug
delivery to specific tissues and tumor sites, in order to reduce drug adverse
side-effects and to improve therapeutic efficacy via the enhancement permeability
and retention (EPR) effect. Liposomes are defined as artificially prepared vesicles
made from a lipid bilayer (Fig.2A) and were first described as such by
Bangham in 1961. More recently, liposomes have attracted considerable
interest as a potential drug carrier.(i7-i9) Liposomes are useful as a DDS tool
owing to their unique properties: 1) hydrophilic drugs can be encapsulated
inside liposomes and hydrophobic drugs can dissolve into the lipid
membrane(20); 2) liposomes are biodegradable and biocompatible because
they are mainly composed with phospholipids and cholesterol; 3) liposomal
surface modification using ligands, such as antibodies,(2i) proteins(22) or
sugar residues,(23) to increase targeted delivery is simple; and 4) changing
liposomal size andlor surface charge to improve biodistribution is easy.
     Particles, including liposomes, were shown to have very short
circulation half-lives owing to rapid liposomal opsonization by plasma
proteins and phagocytosis by fixed tissue macrophages of the
reticuloendothelial system (RES).(20) To solve this problem, it was reported
that liposomal membrane modification with methoxypolyethylene glycol
(PEG)-derivative lipids (PEGylation) is effective (Fig. 2B).(24-26)
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Figure 2. Conventional non-PEGylated and non-targeted
liposomes (A), PEGylated, sterically stabilized liposomes (B) and
ligand-targeted liposomes (C)
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PEGylated liposomes provide a steric barrier against interaction with plasma
proteins such as opsonins and lipoproteins. Because PEGylated liposomes
have prolonged circulation half-lives, that of an encapsulated drug also
increases with a corresponding increase in the duration of drug exposure; this
strategy is able to evade rapid clearance by the RES.(27) Therapies utilizing
this approach have now been licensed, including liposomal doxorubicin and
antifungal agents.
      A further strategy is known as "active targeting", in which particles
with ligands designed to interact with the tumor cells extravasate. This is
therapeutically attractive because it involves bio-molecularly specific
recognition, but no actively targeted agent has received regulatory approval
to date except for monoclonal antibodies. To deliver drugs to specific cancer
cell types, receptor-mediated endocytosis is a promising approach. Some
cell-specific receptors, such as transferrin,(22) folate,(28) lipoprotein,(29)
carbohydrate,(30) and somatostatin (3i'33) receptors are utilized for the specific
cell-targeted delivery of drugs (Fig. 2C).
      Somatostatin receptors (SSTRs) belong to a seven transmembrane
domain G-protein coupled receptor family (SSTRI, SSTR2, SSTR3, SSTR4,
and SSTR5)(34) and can serve as a functional tumor-specific receptor. High
levels of expression of SSTRs are generally detected in a variety of cancers,
including human neuroendocrine tumor, pituitary adenomas, endocrine
pancreatic tumors, gastrointestinal carcinoid, lung carcinoid and
neuroblastoma (Table 1).(35)'(36) MTC tumors also express all the SSTR
subtypes, and the MTC cell line TT overexpresses SSTRI, SSTR2 and
SSTR5.(37) SSTR2 expression was significantly higher than the other SSTR
subtypes in TT cells and was the most frequently detected subtype in human
MTc.(37-3g)
      Octreotide (Oct) has high binding affinity to all SSTR subtypes,(`O)
especially SSTR2 (Kd = O.56 nM).(34) Oct is an octapeptide analogue of
natural somatostatin with markedly increased metabolic stability,(4i) resulting
in an increased plasma-half-life of År1 h in rats(4i) and humans.(42) oct has
been marketed as a diagnostic agent(43-45) and as an anticancer drug for
neuroendocrine tumors: gastric cancer and pancreatic cancer.(46'48) It was
reported that Oct-modified liposomes loaded with anticancer drugs
(cantharidin and dihydrotanshinone I) were efficacious in breast cancer and
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gastric cancer, respectively, in vitro.(3i'33) However, the therapeutic efficacy
ofthese agents in vivo has not yet been reported.
       Furthermore, it was reported that Oct alone could produce an
anti-proliferative action to inhibit the phosphorylation of p70S6K in the
PI3KIAktlmTOR pathway in insulinoma cells (Table 1).(49) The
PI3KIAktlmTOR pathway is activated in many cancers.(49) Therefore,
inhibition of this pathway maybe lead to the suppression of tumor growth.
Moreover, the mTOR inhibitors rapamycin and rapamycin analogs are used
clinically as anticancer drugs worldwide.(49) In Japan, everolimus, a
rapamycin analog, was approved as an mTOR inhibitor for the treatment of
renal cell carcinoma in 2oog. (50)
Table 1. Expression
neuroendocrine tumors
of somatostatin receptors (SSTRs) in
and non-neuroendocrine tumors
Neuroendocrine tumors Pituitary adenomas "
Endocrine pancreatic tumors *
Paragangliomas
Pheochromocytomas
Neuroblastomas *
Medullary thyroid carcinoma *
Non-neuroendocrine tumors Breast carcinoma *
Renal carcinoma *
Lung carcinoma *
Liver carcinoma *
Gastric cancer *
Colorectal carcinoma *
Ovarian carcinoma *
Prostatic carcinoma *
" mTOR-activated cancer
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      MTC overexpresses SSTR2 especially and has sensitivity to CPT-11,
while Oct has high binding affinity to SSTR2. Therefore, it is hypothesized
that Oct-targeted liposomes loaded with CPT-11 might exhibit high
therapeutic efficacy against MTC. The aim of this work is to prepare
Oct-targeted liposome loaded with CPT-11 and liposomal mTOR inhibitor and
evaluate their therapeutic the efficacy for MTC.
      In Chapter 1, the characteristics of Oct-targeted liposome loaded with
CPT- 11 are evaluated in TT cells. In Chapter 2, the anticancer efficacy of the
liposomes is evaluated in TT cells and in TT tumor xenografts. In Chapter 3,
the anticancer efficacy of liposomal mTOR inhibitor is evaluated in TT cells
and lung carcinoma xenografts.
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CHAPER 1
Octreotide-targeted liposomes loaded with CPT- 1 1 for the treatment of
             medullary thyroid carcinoma in vitro
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1. Introduction
      To date, there is no effective approach of treatment for MTC except
for surgery. Chemotherapy for MTC had no inconclusive results. In animal
study, therapeutic approaches for MTC using CPT-11 have been reported.
However, CPT-11 therapy of MTC was failed due to low drug delivery
efficacy to tumor site and severe side effect.(i2)
      For selective delivery of CPT-11 to medullary thyroid carcinoma cell
line (TT cells), Oct-targeted liposome was used, because SSTR2 is known to
overexpress on TT cells.
      To generate formulation, in this chapter, I prepared Oct-targeted
liposomes loaded with CPT-11 (Oct-CL) and investigated the characters such
as size, surface charge, stability, and drug-release efficiency ofthe liposomes
in TT cells. The ligand-modification-ratio optimization and the selective
cellular uptake were investigated. The efficiency of Oct-CL as a selective
drug carrier was evaluated by measuring the association of the liposomes by
flow cytometry, confocal laser scanning microscopy and fluorescence
microscopy. The cytotoxicity of the liposomes in TT cells was also measured.
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2. Experimental section
2.1. Materials
      CPT-11 was a kind gift from Yakult Co,, Ltd. (Tokyo, Japan). Oct-poly
(ethylene glycol) (PEG)34oo-distearoylphosphatidylethanolamine
(Oct-PEG-DSPE)(5i) was purchased from KNC Laboratories. Co., Ltd. (Kobe,
Japan) (Fig. 3). Oct was purchased from Acris Antibodies GmbH (Herford,
Germany). Distearoylphosphatidylcholine (DSPC) and methoxy-PEG2ooo-
DSPE (PEG-DSPE) were purchased from the NOF Corp. (Tokyo, Japan). Chol,
DXR hydrochloride, and Ham's F-12 medium were purchased form Wako Pure
Chemical Industries, Ltd. (Osaka, Japan), Phytic acid (IP-6) solution was
obtained from Nacalai Tesque Inc, (Kyoto, Japan). Fetal bovine serum (FBS)
was purchased from Invitrogen Corp, (Carlsbad, CA, USA). Non-essential
amino acids were purchased from MP Biomedicals. (Cleveland, OH, USA).
Other reagents were of analytical or HPLC grade.
Cys 1ny,Thrf. e.II+,
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             ... "x
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Figure 3. Chemical
(MW - "-5,200)
structure of Oct-PEG34oo-DSPE
2.2. Cell culture and cell preparation
      The TT cell was obtained from the European Collection of Cell
Cultures (ECACC, Wiitshire, UK), This cell line was routinely maintained in
Ham's F-12 medium supplemented with 100/o heat-inactivated FBS at 370C in
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a humidified atmosphere containing 50/o C02.
2.3. Preparation of Oct-targeted liposomes loaded with drug
      Liposomes containing IP-6 (IP-6 liposomes) were formulated
following previously described methods.(52) Briefly, DSPC and Chol at a
molar ratio of 55:45 (80 mg132 mg) were dissolved in ethanol. Ethanol was
removed by rotary evaporation to a smaller volume, and 80 mM IP-6 solution
adjusted to pH 6.5 using triethanolamine was added immediately, followed by
sonication to decrease the size to approximately 150 nm. Then, the extra
liposomal IP-6 suspension was exchanged for HBS buffer (20 mM HEPES,
150 mM NaCl, pH 7.4) by gel filtration chromatography using a Sephadex
G50 column. The concentration of phospholipid (DSPC) of IP-6 liposomes
was determined using a phospholipid C Test Wako (Wako Pure Chemical
Industries, Ltd.), and then total lipid was calculated using DSPC and Chol at
a molar ratio of 55:45. IP-6 liposomes were loaded with DXR or CPT-11 by
incubation with CPT-11 (drug: total lipid = O.6:1, wtl wt) at 600C for 60 min
or with DXR (drug: total lipid = O.2:1, wtl wt) at 600C for 25 min, and then
quenched in ice for 5 min. Unincorporated CPT- 11 or DXR was removed using
a Sephadex G-50 column eluted with saline as the mobile phase.
      Three types of liposomes were prepared; conventional non-PEGylated
and non-targeted liposomes (CL), Oct-targeted Iiposomes (Oct-CL), and
PEGylated, sterically stabilized liposomes (SL) (Fig. 2). Oct-CL was
prepared by incubation of CL with an aqueous dispersion of O.25-1.6 molO/o
Oct-PEG-DSPE with total lipids at 600C for 20 min by the post insertion
technique as reported previously.(53) Above 1.6 molO/o, Oct-PEG-DSPE
precipitates because of its insolubility in water. SL was prepared by
incubation of CL with aqueous dispersion of 1.6 molO/o PEG-DSPE in total
lipids. CL modified with x molO/o Oct-PEG-DSPE of total lipids are
henceforth abbreviated as xOct-CL. For example, O.250ct-CL indicates
liposomes with O.25 molO/o Oct-PEG-DSPE in total lipids (Table 2). Empty
liposomes were prepared using the same protocol but without loading drug.
      The mean diameter and zeta-potential of the resulting liposomes were
determined using an ELS-Z2 (Otsuka, Electronics CO., Ltd. Osaka, Japan) at
25 Å} 10C after diluting the liposome suspension with water. Drug
concentration in the liposomes was determined after disruption of liposomes
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Table 2. 0ct-PEG component (mol O/o) for each liposome
formu1ation
Formulation Oct-PEG34ocrDSPE PEG2ooo-DSPE
CL
O.250ct-CL
O.8Oct-•CL
1 .0Oct- CL
1.2Oct••CL
1.4Oct-CL
1 .6Oct- CL
SL
 o
O.25
O.8
1.0
1.2
1 .4
1.6
 o
o
o
o
o
o
o
o
1 .6
using 10/o of Triton; DXR was determined using a UV-1700 PharmaSpec
(Shimadzu, Kyoto, Japan) at 480 nm(53) and CPT-11 using a fluorometer
(excitation wavelength 375 nm and emission wavelength 535 nm, Wallac
ARVO SX1420 multi-label counter, PerkinElmer Japan, Yokohama, Japan).(53)
No drug leaked out from the liposomes during the Oct-PEG-DSPE insertion
procedure. The final Oct concentration after modification of the liposomes
was determined using an Oct-EIA kit (Peninsula Laboratories, LLC, San
Carlos, CA, USA) after disruption ofthe liposomes by dilution 1:1,OOO in le/o
Triton. About 84e/o, 850/o, and 700/o ofOct ligand was inserted into O.250ct-CL,
O.80ct•-CL, and 1.60ct-CL, respectively.
2.4. Cytotoxicity assay
      TT cells were seeded onto 96-well plates at a density 104 cellslwell for
72 h before addition of the drug. Culture medium was replaced with fresh
medium containing various concentrations of liposomal CPT-11, free CPT-11
or empty liposomes. After 96-h incubation at 370C, the cells were washed
with PBS three times and cultured with fresh medium for 48 h. Then, cell
viability was determined using a WST-8 test (Dojindo Laboratories,
Kumamoto, Japan). All measurement was carried out in quadruplicate. The
500/o growth-inhibitory concentration (IC50) was calculated using the
bootstrap method.(54)
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2.5. Analysis of cellular uptake of liposomes by flow cytometry
      Cells were seeded 6-well plates at a density 104 cells/well for 72 h
before addition of the drug. Cells were incubated with medium (2 mllwell)
containing O.250ct-CL, O.80ct-CL, 1.00ct-CL, 1.20ct-CL, 1.40ct-CL,
1.60ct-CL, or SL at a concentration of 50 pg of DXRIml for 1 or 2 h. In flow
cytometry and confocal laser scanning microscopy studies, as described
below, DXR was used instead ofCPT-11 because CPT-11 is not excited at 488
nm. Subsequently, cells were washed three times with PBS (pH7.4) to
remove unbound liposomes, and the cellular uptake of liposomes was
analyzed using a FACS Calibur flow cytometer (Becton Dickinson, CA, USA)
equipped with a 488 nm argon ion laser and using CELL Quest software
(Becton-Dickinson Immunecytometry System, CA, USA). A total of 10,OOO
events per sample were analyzed. The autofluorescence of cells was taken as
a control. The cells were incubated without liposomes.
      In competitive inhibition experiments, a 20-fold molar excess of free
Oct (84 nmollml medium) was added to 1.60ct-CL loaded with DXR. The
medium in each well (2 ml) contained 50 pg of DXRIml, 4.2 nmol of Oct
originating from 1.60ct-CLIml, and 112 pg of phospholipidlml. A
two-volume excess of empty 1.60ct-CL or SL (258 pl) was added to
1.60ct-CL loaded with DXR. Because all liposomes have a lipid
concentration 194 pg of phospholipidlml, the final concentration of
phospholipid in medium was 582 pglml. This was nearly the maximum
tolerated concentration because greater than O.6 mg of phospholipidlml
induces cytotoxicity. The cells were incubated at 370C for 2 h.
2.6. Confocal laser scanning microscopy
      Cells were seeded in 6-well plates at a density 104 cellslwell for 72 h
before addition ofthe drug. Cells were washed three times with PBS and then
incubated with 1.60ct-CL loaded with DXR in the presence or absence of a
two-volume excess of empty 1.60ct-CL or SL for 2 h at 370C,as described
above. After incubation, the cells were washed three times with PBS and
fixed with 100/o formaldehyde in PBS at room temperature for 15 min. Then,
the cells were washed two times with PBS and coated with Aqua PolylMount
(Polyscience, Warrington, PA, USA) to prevent fading and covered with
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coverslips. The fixed cells were observed using a Radiance 2100 confocal
laser scanning microscope (Bio-Rad, Hercules, CA, USA) with an excitation
wavelength at 488 nm and an emission wavelength at 560 nm utilizing a
LP560 filter.
2.7. Cellular distribution of liposomal CPT-11 observed by
fluorescence microscopy
      Cells were seeded 35 mm glass dishes at 104 cellsldish for 72 h before
addition of the drug. Cells were treated with medium containing 1.60ct-CL
loaded with CPT-11 for 2 h at 370C. After incubation, the cells were fixed and
coated as described above. Cells were examined using an inverted microscope,
ECRIPS TSIOO (Nikon, Tokyo, Japan) with an Epi-Fluorescence Attachment
(Nikon, Tokyo, Japan) a utilizing a UVIA filter.
2.8. In vitro drug release
      The release of the drug from liposomes into phosphate-buffered saline
(PBS, pH 7.4) was monitored by a dialysis method. Dialysis was carried out
at 370C under sink conditions using seamless cellulose tube membranes
SpectralPor CE (MWCO 2000, Spectrum Laboratories, Inc., Rancho
Dominguez, CA, USA). The initial concentration of CPT-11 was 500 pglml.
The sample volume in the dialysis bag was 1 ml and the sink solution was 200
ml. After various time intervals, aliquots were withdrawn and the CPT-11
concentrations were analyzed as described above.
2.9. Statistical analysis
      Data are expressed mean Å} S.D. The statistical significance of data
was evaluated using Student's t test. P Åq O.05 was considered as significant.
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3. Results
3.1. Characterization of Oct-targeted liposomes
      Liposome size and zeta-potential of CL, Oct-CL and SL are listed in
Table 3. The average diameter ofprepared liposomes was approximately
134-154 nm with a narrow, monodisperse distribution (less than O.2
polydispersity indexes). As the Oct concentration increased from O to
1.6 molO/o, the zeta-potential of liposomes decreased. The Oct amount of each
Oct-CL was more than 700/o ofthe theoretical values. The loading efficiencies
of CPT-11 were approximately År 820/o in all liposomes except CL (data not
shown). The average diameter and amount of CPT-11 loaded in all types of
liposomes did not change for at least 1 month at 40C in the dark (data not
shown).
Table 3. Size and zeta-potential of Oct-targeted liposomes
Formulation Size (nm) Zeta-•potential (mV)
CL
O.25Oct-CL
O.8Oct--CL
1.0Octd•CL
1 .2Oct- CL
1 .4Oct-CL
1 .6Oct-CL
SL
t51.9 Å}
141.3 Å}
141.6 Å}
153.9 Å}
134.2 Å}
147.6 Å}
136.6 Å}
144.7 Å}
5.5
6.1
9.4
6.2
5.4
2.4
3.2
1.6
 -5.1 Å} O.1
-
11.2 Å} 3.5
-
17.8 Å} 6.9
-
18.1 Å} 4.3
-
15.3 Å} 1.9
-
17.3 Å} 4.7
-
19.5 Å} 1.3
-
20.1 Å} 1.6
Note; Mean Å} S.D. (n = 3).
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3.2. Effects of Oct surface density of Oct-CL on cellular uptake
     I examined the selectivity of Oct-CL for delivery into TT cells, which
highly overexpress SSTR2, by flow cytometry. As shown in Fig. 4, the mean
fluorescence intensities ofO.80ct-CL, 1.00ct-CL, 1.20ct-CL, 1.40ct-CL and
1.60ct-CL were approximately 1.1-fold, 1.2-fold, 1.2-fold, 1.7-fold and
1.7-fold greater than for SL, respectively, after a 2 h incubation. The cellular
uptake of free DXR was -3 times higher than that of O.250ct-CL (data not
shown). When paying attention to the effects of the Oct surface density of
liposomes on cellular association, a higher Oct surface density, more than 1.4
molO/o of liposomes was more effectively associated with TT cells.
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         (molO/o)
Figure 4. Effect of Oct surface density on cellular association of
Oct-CL
DXR-loaded liposomes modified with various Oct-PEG-DSPE
concentrations (molO/o) were incubated with TT cells at 50 ptgl ml DXR
for 2 h at 37 OC.
Each value represents the mean Å} S.D. (n = 3).
" Differences are statistically significant from SL at P Åq O.05.
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The fluorescence intensities of 1.60ct--CL after a 2 h-incubation increased
2-fold more than after 1 h, whereas that of SL did not increase (data not
shown). This finding indicated that the cellular association of Oct-CL
increased in an incubation time-dependent manner, but that of SL was not,
From this result, 1,60ct-CL was used in the following experiments as Oct-CL,
and SL was used as a control for the 2 h incubation,
3.3. Competitive inhibition study
      First, to investigate the cellular association of Oct-CL via SSTR, a
competitive inhibition study was performed using free Oct as a competitive
inhibitor, In the presence of a 20-fold excess of free Oct (84 nmollml
medium) with 2 h incubation, a competitive effect, a decrease of cellular
uptake of Oct-CL, was not observed (Fig. 5).
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Figure 5. Association of Oct-CL loaded with DXR with TT cells
in the presence or absence of free Oct by flow cytometry
1.60ct-CL loaded with DXR was incubated in the presence of a 20-fold
excess of free Oct (84 pM) at 50 pglml DXR for2 h at 370C.
Untreated indicates auto fluorescence of untreated cells.
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     Next, I tried to use Oct-CL without drug loading (empty Oct-CL) as a
competitive inhibitor, because addition of drug-loaded liposomes has the
possibility of increasing the cytotoxicity due to DXR. Fig. 6A illustrates the
scheme of the competitive cellular association of Oct-CL loaded with DXR
with empty Oct-CL. The cellular uptake of Oct-CL loaded with DXR in the
presence of two excess volumes of empty Oct-CL (i) was compared with that
of empty SL (ii) by flow cytometry (Fig. 6B) and confocal microscopy (Fig.
7). As shown in Figure 6B, the mean fluorescence intensities of DXR loaded
with Oct-CL in the presence of empty Oct-CL decreased by approximately
half compared with in the presence of empty SL. This finding indicated that
the cellular uptake of Oct-CL loaded with DXR was blocked significantly by
empty Oct•-CL compared with empty SL,
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To confirm differences in the cellular uptake of Oct-CL loaded with DXR in
the presence ofempty Oct-CL or SL, intracellular localizations were observed
by confocal microscopy (Fig. 7). The presence of empty Oct-CL decreased the
localization of DXR-loaded Oct-CL in the nucleus (red fluorescence of DXR)
compared with that of empty SL, corresponding to the results of Fig. 6B (i)
and (ii), respectively.
Figure 7. Effects of empty 1.60ct-CL (i) or SL (ii) on the
cellular association of 1.60ct-CL loaded with DXR with TT cells
determined by confocal microscopy
The experimental conditions were the same as for Figure 6B.
Scale bar denotes 100 pm.
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3.4 Drug release from liposomal CPT-11
       Before the investigation of cellular uptake of Oct-CL and SL, the
release of drug from each liposome was examined. The profiles of CPT-11
release versus time are presented in Fig. 8. Both Oct-CL and SL showed slow
drug release, about 170/o drug release for 24 h in PBS at 370C. There were no
significant differences between Oct-CL and SL in drug release at each time
point. This result suggested that 1.6molO/o Oct-modification did not affect
drug release from liposomes.
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 Figure 8, Percentage of CPT-11 released from 1.60ct-CL and SL
 as a function time at 370C
 Each value represents the mean Å} S.D. of three experiments.
3.5. Cellular uptake of Oct-CL
      Next, I tried to observe the cellular distribution of liposomes loaded
with CPT-11 by fluorescence microscopy (Fig. 9). TT cells were incubated
with Oct-CL loaded with CPT-11 for 2 h at 370C. Blue fluorescence due to
CPT-11 (Fig. 9A) was observed weakly in Oct-CL loaded with CPT-11 at the
same location as TT cells (Fig. 9B). This finding indicated that Oct-CL
loaded with CPT- 11 was taken up into the cells as well as Oct-CL loaded with
DXR.
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Figure 9. Cellular uptake of liposomal
fluorescence microscopy
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370C. Blue fluorescence; location ofCPT-11.
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3.6. Effect on cytotoxicity of Oct-targeted liposomes
      To evaluate the cellular uptake of Oct-CL loaded with CPT-11, the
cytotoxicity with TT cells was measured using a WST-8 assay. The doubling
time of TT cells is 83 h; therefore, a 96-h incubation was set in this
experiment, As shown in Table 4, free CPT-11, Oct-CL, and SL increased
cytotoxicity in an incubation time-dependent manner. Free CPT-11 showed
higher cytotoxicity than liposomal CPT•-11 with 48-h and 72--h incubations.
After a 96-h incubation, the IC50 value of Oct-CL was the lowest (1.05 Å} O.47
pM), whereas free CPT-11 (3.76 Å} O,61 pM) and SL (3.05 Å} O.28 pM), gave
the similar cytotoxicity results. Therefore cytotoxicity of Oct-CL loaded with
CPT-11 may be due to cellular uptake of liposomal CPT-11. In addition,
8.4 pM Oct originating from empty 1.60ct-CL significantly decreased TT cell
viability to 600/o after a 96-h incubation compared with empty SL
(corresponds to the amount of PEG-DSPE ofOct-CL) (Fig. 10). In the case of
more than about 12 pM Oct using 1,6 Oct-CL (total lipid 1,02 mM),
cytotoxicity of liposomes was observed due to the lipids. On the other hand,
cytotoxicity of free Oct was not observed independent of the Oct
concentration (data not shown).
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Table 4. IC50 of free CPT-11 and liposomes loaded with CPT-11
on TT cells after various incubation times
Fo rm u lation IC50 (pM)
48h 72 h 96 h
Free CPT-M
1.60ct-CL
SL
 7.43 Å} 6.73
29.05 Å} 19.40
22.50 Å} 19.50
5.10 Å} 1.85
8.72 Å} 1.14
8.65 Å} 2.26
3.76 Å} O.61
1.05 Å} O.47t
3.05 Å} O.28
Note; Mean Å} S.D. (n = 4).
*, Differences are statistically significant from SL at P Åq O.05.
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Figure 10. Effect of Oct concentrations on cell viability of
1.60ct-CL compared with SL
TT cells were incubated with ernpty 1.60ct-CL or empty SL for 96 h at
37eC.
* Differences are statistically significant at P Åq O.05.
Each value represents the mean Å} S.D. (n=4).
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4. Discussion
      In this chapter, I prepared Oct-CL loaded with CPT-11 and
demonstrated that high Oct-surface-density significantly increased the
cellular association of Oct-CL via SSTR and approximately 2-fold higher
cytotoxicity when compared with free CPT-11 and PEGylated liposomes (SL)
with TT cells using a 96-h exposure period. Recently, it was reported that O.5
molO/o Oct-modified liposomes, loaded with anticancer drug were selectively
taken by the cells and were effective for the treatment of SSTR-positive
breast cancer, gastric cancer and lung carcinoma. (3i'33) In the case of
transferrin-targeted liposomes modified with transferrin-PEG-DSPE, the
cellular uptake of liposomes was dependent on the concentration of
transferrin-PEG-DSPE.(55) Therefore, I increased the concentration of
Oct-PEG-DSPE in the liposomes and found that the cellular uptake of the
Oct-CL increased more effectively with high Oct-surface-density, more than
1.4 molO/o (Fig. 4).
      There were two striking observations in this study. First, the cellular
uptake of Oct-CL was significantly inhibited by empty Oct-CL. The
competitive inhibition study of cellular uptake of ligand-modified liposomes
was generally done using excess free ligands, not using ligand-liposomes
such as Oct-CL. For example, it was reported that the cellular uptake of
transferrin-targeted liposomes was inhibited by 20-fold excess transferrin.(55)
In this study, 20-fold excess free Oct did not inhibit the cellular uptake of
Oct-CL (data not shown). In the competitive inhibition study via SSTR, 100-,
1,OOO- or 1,OOO,OOO-fold excess of Oct was used.(56-58) These experiments had
a very high cost, and Oct has been reported to be used as an anticancer
drug.(59' 60) This information suggested that the use of such an excess Oct was
not suitable for competition of the cellular uptake of Oct-CL because of
increases in cytotoxicity. Gabizon et al.(6i) reported that liposome binding is
multivalent, in other words, several ligands contribute to cellular uptake, and
the overall affinity for the target cell is the product of the individual
affinities of the ligands participating in binding. It could be predicted that the
affinity of free Oct and Oct-CL to SSTR are not the same. In this regard, I
used empty Oct-CL and empty SL as a competitive inhibitor and as a control,
respectively (Fig. 6). The cellular uptake of 1.60ct-CL loaded with drug (Oct
concentration 7.2 pM) was inhibited significantly by empty Oct-CL with 14.4
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pM Oct, compared with empty SL. This finding indicated that Oct-CL
associated via SSTR, and the affinity of Oct-CL to SSTR was substantially
higher than that of free Oct.
      Second, the cytotoxicity Oct-CL loaded with CPT-11 incubated for 96
h was higher than that of free CPT-11 and SL loaded with CPT-11. The
cytotoxicity of free CPT-11 increased in an incubation-time dependent
manner from 24 h to 96 h in TT cells, as reported previously.(62) The long
incubation times may lead to metabolization of CPT-11 to SN-38; the active
form of CPT-11 in TT cells. As a result, the cytotoxicity of free CPT-11 after
the 96-h incubation increased six-fold compared with at 48 h, and that of
Oct-CL increased --25 times, resulting in the highest cytotoxicity among free
CPT-11 and SL. These findings suggested that a long incubation time caused
CPT-11 release from the taken liposomes, which was converted to the active
form SN-38, and consequently increased the cytotoxicity. The
receptor`-mediated endocytosis mechanism of Oct-CL significantly facilitated
cellular uptake and the cytotoxic potential of CPT-11 compared with SL.
      The question remains why 1.60ct-CL showed higher cytotoxicity than
free CPT- 11, which freely diffuses into cells. Empty 1.60ct-CL as a control of
1.60ct-CL (correspond to 4.2 pM of Oct-PEG-DSPE) at 96-h incubation in
the cytotoxicity experiments was shown to have no effects (Fig. 10). However,
empty 1.60ct-CL showed higher cytotoxicity than empty SL liposomes
modified with PEGd-lipid corresponded to Oct-PEG-lipid of 1.60ct-CL at 96-h
incubation, at the concentration where free Oct did not show cytotoxicity,
suggesting that Oct as a ligand showed cytotoxicity.
      With regard to Oct activity, Oct was reported to produce an
anti-proliferative action in insulinoma cells and pituitary tumor cells.(60' 6i)
These findings suggested that Oct might show an anti-proliferative effect in
TT cells. From this, Oct may cause empty Oct-CL to show a stronger
cytotoxicity than empty SL because Oct-CL were taken up effectively via
SSTR. However, further experiments are needed to clarify these points in
vltro.
      In an in vitro study, Oct increased selectively the cellular association
ofliposomal CPT-11 (Fig. 4), and empty 1.60ct-CL decreased the viability of
TT cells (Fig. 10). These findings suggested that Oct-modification of
liposomal CPT-11 improved therapeutic efficacy for MTC in vitro.
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5. Conclusion
      In Chapter 1, the present study showed that higher concentrations of
modified Oct-CL associated effectively with TT cells via the somatostatin
receptor and had higher cytotoxicity than free CPT- 11 or PEGylated liposome,
SL. These findings indicated that Oct-targeted liposomes loaded with CPT-11
might offer considerable potential for MTC chemotherapy because
cytotoxicity of both CPT-11 and Oct was enhanced by effective cellular
uptake via the somatostatin receptor.
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CHAPER 2
Octreotide-targeted liposomes loaded with CPT-1 1 for the treatment
          ofmedullary thyroid carcinoma xenografts
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1. Introduction
      As described in Chapter 1, 1,6 molO/o Oct modified liposomes loaded
with CPT-11 (Oct-CL) had a potential of therapeutic treatment for MTC.
Therefore, I examined the therapeutic efficacy of the liposomes for MTC
xenografts. It is known that liposomal drug can improve drug delivery
efficiency compared with free drug. It is also well known that intravenously
injected PEGylated liposomes, SL can passively accumulate into tumor tissue
due to the EPR effect (Fig. 11).(65) Therefore, the antitumor effects Oct-CL
were compared with these of free CPT-11, non-PEGylated liposome loaded
with CPT-11 (CL), and SL to clarify whether the active-targeting Oct-CL was
superior to CL and the passive targeting SL,
     It was also observed in Chapter 1, that non-drug loaded Oct-CL; empty
Oct-CL, showed higher cytotoxicity compared with empty SL in TT cells (Fig
10), To gain more insight into tumor suppression, I examined the mechanism
of cytotoxicity of the Oct ligand, In this Chapter, the function of Oct ligand
in Oct-CL from viewpoints of therapeutic efficacy and the biodistribution and
conversion of CPT-11 in MTC tumor xenografts after the intravenously
injection of Oct-CL or SL, were observed. Furthermore, the cytotoxicity
mechanism of Oct ligand using empty Oct-CL in vitro and in vivo, was
assessed.
(A) Normal vasculature
EPR effe ct ( - )
(B)Tumorvasculature ..,, Åq}• particle
                              C7, "
                                        ew
                                     trt "
                            EPR eflfect (+)
Figure 11. Enhancement permeability and retention (EPR) effect
in normal vasculature (A) and tumor vasculature (B)
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2. Experimental section
2.1. Materials
      CPT-11, DSPC, PEG-DSPE, IP-6 and Chol were the same ones in
Chapter 1. SN-38 was purchased from Wako Pure Chemical Industries, Ltd.
(Osaka, Japan). Other reagents were of analytical or HPLC grade.
2.2. Preparation of liposomal CPT-11
      Three types of liposomal CPT-11 (CL, SL and Oct-CL) were prepared.
Liposomal preparation methods were described in Experimental section of
Chapter 1. Liposomes were incubated with 1.6 molO/o Oct-PEG-DSPE for
Oct-CL or •1.6 molO/o PEG-DSPE for SL at 600C for 25 min.(66) Empty
liposomes were prepared using the same protocol but without loading drug.
2.3 . Cytotoxicity assay
      Cytotoxicity on TT cells (human MTC cell line) was carried out using
free Oct or empty liposomes. Cells were incubated for 48 h at the different
concentrations of free Oct, empty liposomes in the presence or absence of 1.5
pM CPT-11, which corresponded to one-tenth of the 500/o growth-inhibitory
concentration.(66) Lipid amount of empty SL corresponded to that of empty
Oct-CL. Cell viability was measured by the same protocol described in
Chapter 1.
2.4. Animals
      All animal experiments were performed with approval from the
Institutional Animal Care and Use Committee at Hoshi University. TT cells (1
Å~ 107) were inoculated subcutaneously into female ICR nulnu mice (6 weeks
of age, Oriental Yeast Co., Ltd., Tokyo, Japan).
2.5. Antitumor effects
      When the average tumor volume was approximately 100 mm3,
Experiment 1; CL or Oct-CL was injected intravenously at a dose of 10 mg
CPT-111kg twice at three-day intervals (24.1 mg lipidlkglinjection). Free
CPT-11 (30 mg CPT-111kg) and saline were injected intravenously three times
at three-day intervals. The data of free CPT-11-tretated and saline-treated
mice were referring to our previous data.(62) Experiment 2; Oct-CL or SL was
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injected intravenously at a dose of 10 mg CPT-111kg in two times at three-day
intervals (23.9 mg lipidlkglinjection). Experiment 3; Empty Oct-CL or empty
SL was injected intravenously (23.5 mg lipid and 867 nmol Octlkglinjection,
corresponding to Oct ligand amount of 1.60ct-CL) in two injections at
three-day intervals. SSTR2-mRNA was detected in TT tumor xenografts by
RT-PCR analysis (data not shown).
      Tumor volume and body weight were measured for individual animals.
Tumor volume was calculated using the following equation: volume = 112 ab2,
where a is the long diameter and b is a short diameter. The mean increase in
life span (O/olLS) was calculated using the formula; 100 x {(median day of
death in treated tumor-bearing mice) - (median day of death -in control tumor
bearing-mice)}1(median day of death in control tumor bearing-mice).
2.6. Biodistribution in TT xenograft mice
      When the average tumor size reached approximately 100 mm3, mice
were injected with Oct-CL or SL intravenously at a dose of 10 mg CPT-111kg.
At 6 h and 24 h after a single injection, blood was collected. Tumor, liver,
kidneys, lung and spleen were excised and homogenized. CPT-11 and SN-38
were extracted using ice-cold acidic methanol and analyzed by HPLC methods,
as reported previously.(52) The CPT-11 dose O/olml plasma or g tissue was
calculated as the amount of CPT-11 per total plasma volume (ml) or per total
tissue weight (g), respectively, from that of injected liposomal CPT-11.(52)
2.7. Distribution ofliposomal CPT-11 in TT xenograft mice
      When the average tumor size reached approximately 150 mm3, mice
were treated with Oct-CL or SL intravenously at a dose of 10 mg CPT-111kg.
At 6 h and 24 h after a single injection, tissues were collected and prepared as
20 pm frozen sections. Tissue sections were examined using an inverted
microscope, ECRIPS TS100 (Nikon, Tokyo, Japan), with an Epi-Fluorescence
Attachment (Nikon) a utilizing a UVIA filter.
2.8. Conversion activity ofCPT-11 by carboxylesterase
      The conversion activity of CPT-11 by carboxylesterase (CPT-CE
activity) in TT cells, normal liver and TT tumor tissue was measured by the
Guichard method.(67) Briefly, TT cells (4 Å~ 104 cells) were homogenized. The
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homogenates were centrifuged at 20,OOO g for 30 min at 40C to obtain
cytosol.
      Cytosolic protein (3 mg/ml, 80 pl) and 5 pM CPT-11 (20 pl) were
mixed and incubated at 370C for 1 h. Then, ice-cold acidic acetonitrile was
added to stop the reaction. SN-38 produced during the incubation was
measured by an HPLC method, as previously reported.(52) TT tumor tissue and
liver were excised and homogenized. Cytosol from the TT tumor tissue and
normal liver, which was perfused with ice-cold saline to remove blood, was
prepared using the same protocol as for the extraction protocol in TT cells.
CPT-CE activity in normal liver and TT tumor tissue was measured using the
same protocol as for the assay protocol in TT cells.
2.9. Effects of octreotide-targeted liposomes on the PI3K/AktlmTOR
pathway in TT cells and TT tumors
      TT cells were incubated with serum-staved (O.10/o FBS) cell medium
with empty Oct-CL, empty SL, CPT- 11 or SN-38 for 24 h at 370C. Cell lysates
were prepared with ice-cold RIPA buffer (20 mM Tris-HCI (pH 7.5), 150 mM
NaCl, 10/o Triton X-100 containing protease and phosphatase inhibitors),
separated by SDS-PAGE, and blotted using standard procedures.(68) Primary
antibodies were against Akt, Tuberous sclerosis complex 2, tuberin (TSC2),
p70S6K, phosphorylated Akt (Ser473), phosphorylated TSC2 (Thr1462) and
phosphorylated p70S6K (Thr389) (all made in rabbits; Cell Signaling
Technology, Beverly, MA, USA). Horseradish peroxidase-conjugated
secondary antibody was used to detect the primary rabbit antibody (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA, USA). All proteins were detected
by peroxidase-induced chemiluminesence (Super Signal West Pico
Chemiluminescent substrate, Pierce).
      When the average tumor size reached approximately 150 mm3, empty
Oct-CL or empty SL was injected intravenously once (23.5 mg lipid and 867
nmol Oct/kg). At 24 h after injection, tumor tissue was collected and
homogenized in RIPA buffer. Western blotting was performed using the same
protocol as for the in vitro study.
2.10. Statistical analysis
      The statistical significance ofdifferences in the data was evaluated by
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analysis using one-way ANOVA in combination with the Tukey-Kramer test.
' P Åq O.05 and " P Åq O.Ol were considered as significant. Kaplan-Meier
analysis was performed using GraphPad Prism, version 4.0, (GraphPad
Software Inc. San Diego, CA).
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3. Results
3.1 Size and zeta-potential of liposomes
      Two types of liposomes, 1.6 molO/o Oct-PEG-DSPE modified Oct-CL
and 1.6 molO/o PEG-DSPE modified SL were prepared. The average particle
size of each liposome was e-146 nm with a narrow monodisperse distribution
(data not shown). The zeta-potential and drug entrapment efficiency of each
liposome formulation was approximately -14 mV and År800/o, respectively
(data not shown). There were no significant differences between Oct-CL and
SL in terms of particle characters such as particle size, zeta-potential or drug
entrapment efficiency, except for active-targeting ability.
3.2. Therapeutic efficacy of liposomal CPT-11
      At first, the antitumor effect of free CPT-11, CL and Oct-CL were
evaluated in TT xenografts. Oct-CL reduced the tumor size in mice after the
final injections, and the reduced tumor size was maintained until the day 23
after the treatment, whereas CL maintained tumor growth suppression only
until at day 10 after the treatment. Oct-CL suppressed tumor growth
significantly compared with CL, free CPT-11 or saline (Fig. 12). Body weight
losses were not observed in any of the groups (data not shown). Median
survival for mice treated with saline was 68 days, compared with 88 days for
free CPT-11-treated, 103 days for CL-treated mice and 217 days for
Oct-CL-treated mice. Treatment with liposomal CPT-11 (CL and Oct-CL)
significantly increased survival time. O/olLS of Oct-CL-treated group (221.5)
was significantly improved compared with that of the CL-treated (52.6) and
free CPT-11-treated (30.4) groups.
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Figure 12. Effect of Oct-modification of liposomal CPT-11 on
antitumor activity in mice bearing TT cells
Antitumor activity of Oct-CL was compared to that of CL or free drug.
Liposomal CPT-11 (A: 10 mglkg Oct-CL, e: 10 mglkg CL) was injected on
days 24 and 27, and free CPT-11 (D: 30 mglkg) and saline (o) were injected
three times. Arrows indicate the day ofdrug injections.
Each value represents the mean Å} S.D. (n = 4).
* Differences are statistically significant from free CPT-11 at P Åq O.05.
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     Next, the antitumor effect of Oct-CL was compared with SL in TT
tumor xenografts. Oct-CL exhibited significantly stronger suppression of
tumor growth at day 31 to 52 after the inoculation compared with saline and
at day 31 to 39 compared with SL (Fig. 13A). Body weights losses were not
observed (Fig. 13B). Oct-CL treatment significantly improved median
survival up to 212 days, compared with 198 and 121 days observed in
SL-treated group (P Åq O.Ol) and saline-treated group (P Åq O.05), respectively
(Fig. 13C).
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Figure 13. Therapeutic efficacy ofadministration ofOct-CL or SL
Oct-CL, SL or saline, was injected intravenously into mice
Treatment effects of liposomal CPT-11 on tumor size (A), body weight (B), and survival
rate (C). The formulations used were Oct-CL (o), SL (-) and saline (A).
Each value represents the mean Å} S.D. (n = 6).
'P Åq O.05 versus Oct-CL-treated mice.
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3.3. Biodistribution of liposomal CPT--11
      The biodistribution of CPT-11 and SN-38 was examined in TT
xenografts at 6 h or 24 h after intravenous injections of Oct-CL or SL loaded
with CPrl]-11, CPT-11 was highly distributed in the liver and spleen (Fig, 14B),
Frozen sections of tumors in Oct-CL treated group were observed with blue
fluorescence ofCPT-11 than those in SL treated group, both 6 h and 24 h after
injection (Fig. 14A). SN-38 could not be detected under this condition,
CPT-11 blue fluorescence was weak and was not enough to show the
significant difference in CPT--11 tumor accumulation between Oct-CL- and
SL-treated groups, Therefore, next I measured concentrations of CPT-11 and
SN-38 in tumor tissues and other organs by HPLC method. Six hours after
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injection, CPT-11 levels in the liver of Oct-CL•-treated mice were
significantly higher than that of SL-treated mice (P Åq O.05) (Fig. 14B and C).
CPT-11 and SN-38 levels in tumor tissue of Oct-CL-treated mice were
significantly higher, 3.7-fold and 2-fold, respectively, than compared with
that of SL-treated mice (P Åq O.Ol) (Fig. 14B and C). On the other hand, the
kidney distribution of CPT- 11 in Oct-CL-treated mice was significantly lower
than that of SL-treated mice (P Åq O.Ol). Twenty-four hours after injection,
SL-treated mice maintained a higher CPT-11 level in the plasma (7.1 Å} 2.40/o
doselml), whereas Oct-CL-treated mice showed approximately half the
CPT-11 plasma concentration of SL-treated mice (P Åq O.05). Tumor CPT-11
concentration between the Oct-CL- and SL-treated groups was not
significantly different, but the SN-38 concentration in Oct-CL-treated group
was significantly higher, 2.2-fold, than in SL-treated mice (P Åq O.Ol).
3.4. In vitro conversion of CPT-11 to SN-38 in TT cells, the liver
and TT t-mor tissues
      In the biodistribution study, higher SN-38 accumulation was observed
in tumor tissues 6 h and 24 h after administration of Oct-CL than that of SL.
To confirm the conversion of CPT-11 to SN-38 in TT cells, I analyzed the in
vitro conversion of CPT-11 to SN-38 in TT cells. The cytosol of TT cells
showed the conversion of CPT-11 to SN-38 at a rate of2.53 Å} O.09 pmollhlmg
protein (data not shown). TT cells per se were found to have the conversion
activity of CPT-11 to SN-38. With regard to TT tumor tissue, the conversion
rate in the liver was approximately 8.50/o of the CPT-11 that was initially
added to the reaction mixture (100 pmol CPT-11) (Fig. 15). Interestingly, the
conversion of CPT-11 to SN-38 activity in TT tumor tissue was O.8-fold that
of the liver, suggesting that CPT-11 loaded into Oct-CL was accumulated in
the tumor directly by active targeting of Oct-CL, and was converted into
SN-38. The negative control (initially adding the stop solution before the
addition of CPT-11 and incubation) showed no production of SN-38.
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Figure 15. CPT-1 1 converted by carboxylesterase activity
Cytosol was incubated with CPT-1 1 at 370C for 1 h.
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3.5. Effects of Oct ligand of liposomes on growth inhibition and
the phosphorylation of p70S6K
      As shown in Fig. 16A, empty Oct-CL exerted growth inhibitory effect
on TT cells in a dose-dependent fashion of Oct ligand. Furthermore, addition
of 1.5 pM CPT-11 potentiated the growth inhibition activity of empty
Oct-CL, having led to an additional approximately 200/o of reduction in cell
viability. In contrast, empty SL did not exert growth inhibitory effect in the
presence or absence of CPT-11 (Fig. 16B). Free Oct showed growth
inhibitory effect only at high-concentration, 100 pM (Fig. 16C), but showed
no synergistic effect with CPT-11.
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      In many cancers, the PI3KIAktlmTORIp70S6K pathway contributes
to cell proliferation and growth, and this pathway is activated by
phosphorylation ofAkt, TSC2 or p70S6K proteins.(70)(7i) Therefore, I tried
to clarify the effects of Oct ligand on phosphorylation of proteins in TT cells
and TT tumors by Western blotting, using empty Oct-CL, empty SL, CPT-11
or SN-38. As shown in Fig, 17A, empty SL and empty Oct-CL did not affect
the protein phosphorylation of neither Akt nor TSC2 in TT cells. Only empty
Oct-CL (correspond to O.42 pM Oct ligand) strongly inhibited the
phosphorylation of p70S6K at the Thr389 site whereas total p70S6K was not
affected. In TT tumor tissue, whereas empty Oct-CL or empty SL did not
affect total protein p70S6K, mice injected with empty Oct-CL showed a
decrease in the level ofphosphorylated p70S6K, but those with empty SL did
not (Fig. 17B). However, the empty Oct-CL and the empty SL did not exhibit
antitumor effects under this experiment condition in TT tumor xenografts
(Fig. 18).
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Figure 17. Effects of empty SL or empty Oct-CL on Akt-TSC2-p70S6K
in TT cells (A) and TT tumor tissue (B)
TT cells were treated with empty Oct-CL (correspond to O.42 pM of Oct-PEG-DSPE),
empty SL liposomes modified with O.42 pM PEG-DSPE, CPT-11 (13 pM) or SN-38
(O.14 pM) for 24 h, TT tumor-bearing mice were injected with empty Oct-CL 24 h
before the experiment.
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4. Discussion
      In this chapter, I demonstrated that Oct-CL showed the early and
higher accumulation of CPT-11 in the tumor, enhanced the anti-tumor effect,
and significantly prolonged the median survival compared with free CPT-11,
CL and SL. Moreover, the mechanism of action of Oct associated with
liposomes was investigated by measuring the biodistribution of Oct-CL and
the phosphorylation of proteins after empty Oct-CL treatment.
      In this Chapter, Oct-CL showed a significantly higher distribution to
TT tumor tissue compared with SL at least until 6 h after inj ection. This result
suggested that Oct-CL accumulated rapidly in the tumor after injection as a
result of Oct-targeting, whereas SL accumulated slowly in the tumor by the
EPR effect for 24 h. Twenty-four hour after injection, there was no significant
difference in CPT-11 tumor accumulation between Oct-CL and SL. CPT-11
level of Oct-CL in the tumor was sustained for 24 h after injection.
      Why was the SN-38 concentration of tumors in Oct-CL-treated mice
significantly higher than that of SL-treated mice at 24 h even though the
CPT-11 concentration was similar? Generally, it is reported that CPT-11
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conversion to SN-38 mainly occurs through the action of liver carboxyl
esterase.(67) Accordingly, it can be regarded that SN-38 transformed in the
liver accumulated in the tumor. When the accumulation of CPT- 11 in the liver
was similar between Oct-CL- and SL-treated mice, converted SN-38 in the
liver should be present in similar amounts, and, therefore, the amount of
SN-38 accumulating in tumor should be similar. As described in Chapter 1,
there were no significant differences between Oct-CL and SL in terms of drug
release over 48 h at 370C in PBS. Furthermore, an in vitro conversion study
showed that the conversion activity of CPT-11 to SN-38 in TT tumor tissue
was O.8-fold that ofthe liver. From these findings, higherSN-38 concentration
of Oct-CL at 24 h may reflect early direct distribution of Oct-CL to tumor
tissue by SSTR-targeting. To the best of our knowledge, this is first report
about CPT-11 conversion activity in TT cells and TT tumor tissue.
      When I examined other tissues, there were significant differences
between Oct-CL- and SL-treated mice in kidneys and liver distribution. The
CPT- 11 concentration in the kidneys ofOct-CL-treated mice was significantly
lower compared with that of SL-treated mice. Because the kidney is known to
express SSTR2,(69) Oct-CL might be selectively and rapidly distributed to the
kidneys, as well as to the tumor, and then excreted more rapidly than in
SL-treated mice. With regard to the liver, Oct-CL accumulated to a higher
level in the liver than with SL because SL was modified with Oct ligand and it
may be taken up by the RES.
      Empty Oct-CL exerted cell growth inhibition at low-concentrations
(O.42 and 4.2 pM), while free Oct did not show it below 100 pM (Fig. 15).
Empty Oct-CL showed effectively cell growth inhibition compared with free
Oct, suggesting that affinity of empty Oct-CL to SSTR may be higher than
that of free Oct. Phosphorylation of p70S6K is reported to activate cell
growth and proliferation.(70) p70S6K is the downstream protein of the
PI3KIAktlmTOR pathway (Fig. 19) and phosphorylation of p70S6K is
generally used as a marker of the inhibition of the PI3KIAktlmTORIp70S6K
pathway.(7i) Treatment with empty Oct-CL caused the suppression of
phosphorylation ofp70S6K in vitro and in vivo (Fig. 17) but empty SL did not.
Therefore, this result suggested that empty Oct-CL inhibited cell growth and
proliferation by suppressing the phosphorylation of p70S6K in TT cells and
TT tumor tissue. In other words, the targeting-ligand Oct had not only tumor
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Figure 19. The PI3K/Akt/mTOR pathway in insulinoma cell line
targeting activity but also assisted with the antitumor effects. Therefore, the
Oct ligand has dual functionality,
     However, the treatment with empty Oct-CL did not exhibit anti-tumor
effect under this condition (Fig. 18), For MTC, it was reported that clinically
subcutaneous injection of free Oct at 500 pg (= 458 nmol)/day for 90 days,
and 150 pg (= 137 nmol)lday for 6 months showed no effects to therapeutic
efficacy.(59' 60) In this therapeutic study, Oct originated from Oct-CL was
injected twice as 867 nmol Oct/kglday, From these different schedules, it is
difficult to judge the therapeutic efficacy by Oct alone in our study.
     Fig. 20 illustrates the proposed antitumor effects of Oct-CL for MTC.
Oct-CL was selectively associated with TT cells, CPT-11 was released from
Oct-CL, and then CPT-11 was converted to SN-38 by carboxylesterase in TT
tumor. SN-38 produced in the tumors showed cytotoxicity. Oct-CL suppressed
the phosphorylation of p70S6K. These suppressions led to inhibition of cell
growth and proliferation, which assisted in anti-tumor effects for MTC using
Oct-CL loaded with CPT-11.
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5. Conclusion
      In Chapter 2, it was showed that Oct-CL exhibited enhanced drug
accumulation in tumor, and CPT-11 in tumor was converted into an active
metabolite O.8-fold that in the liver. Oct-targeted liposome exhibited higher
therapeutic efficacy with the strong antitumor effect and the significant
improvement of median survival, than free CPT-11, non-PEGylated liposome,
CL and PEGylated liposome, SL in TT tumor xenografts. Empty Oct-CL in TT
cells and tumor decreased the level of phosphorylated p70S6K. The
improvement in therapeutic efficacy was due to the dual functions of Oct; the
rapid and highly selective distribution of Oct-CL to tumor by SSTR-targeting
and the assistance of cell growth suppression by mTOR inhibition.
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CHAPER 3
Liposomal everolimus for the treatment oflung carcinoma and
          medullary thyroid carcinoma in vivo
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1. Introduction
      As described in Chapter 2, empty Oct-targeted liposomes (empty
Oct-CL) decreased the level of phosphorylated p70S6K in TT cells and
tumors. Oct, a ligand of SSTR exhibited mTOR inhibition. However, empty
Oct-CL did not show therapeutic efficacy to MTC in vivo.
      Rapamycin interferes with the PI3KIAktlmTORIp70S6K signaling
cascade, which activates cell growth and cell proliferation.(70'7i) Although
rapamycin was discovered more than 30 years ago, renewed interest in this
pathway is evident by the numerous rapamycin analogs (rapalogs) developed
recently.(72) Some rapalogs have recently become of significant interest as
potential anti-cancer drugs.(73-75) Everolimus (Fig. 21) is a rapalog
40-O-(2-hydroxyethyl) derivative of rapamycin. Everolimus was approved as
only anticancer agent based on an mTOR inhibition in Japan in 2009.
      Two problematic features of rapamycin and rapalogs are their low
water solubility (everolimus, 9.6 pglml) and low biological availability.(76• 77)
Therefore, to circumvent such unsuitable characteristics, rapamycin was
entrapped in liposomes, polymer micells or albumin-bound
nanoparticles.(78-80) However, so far, to our best knowledge, there is no report
of the antitumor efficacy in vivo of liposomal rapamycin or other particulated
rapalogs.
      Therefore, I examined the antitumor effect of liposomal everolimus as
an mTOR inhibitor in vitro and in vivo. In addition, the cytotoxicity of
co-administration of everolimus and CPT-11 was examined in vitro, to
compare with the previous results of combination of empty Oct-CL and
CPT•- 1 1 .
      In this Chapter, I examined the antitumor activity of a liposomal
formulation of everolimus in vitro and in vivo.
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2. Experimental section
2.1. Materials
      Everolimus was purchased from LC laboratories (Woburn, MS, USA).
Soybean L-alpha-lecithin (soybean lecithin) was purchased from Calbiochem
(Darmstadt, Germany). RPMI medium was purchased form Wako Pure
Chemical Industries, Ltd. (Osaka, Japan). CPT- 11, DSPC, mPEG-DSPE, Chol,
Ham's F-12 medium and FBS were the same ones described in Experimental
section of Chapter 1 and 2. 0ther reagents were analytical or HPLC grade.
2.2. Cell cultures and cell preparations
      Culture of TT cells was described in Experimental section of Chapter
1. Human-derived small cell lung carcinoma NCI-H446 and breast cancer
MCH-7 were from American Type Cellular Collection (ATCC, Manassas, VA,
USA). NCI-H446 cells and MCF-7 cells were maintained in RPMI medium.
The medium was supplemented with 100/o heat-inactivated FBS at 370C in a
humidified atmosphere containing 50/o C02.
2.3. Preparation of liposomal everolimus
      Four kinds of liposomal everolimus were prepared. The liposome
compositions by molar ratio were DSPC/ChollPEG-DSPE (52:42:6, D-SL),
DSPCIChol (55:45, D-CL), soybean lecithinlChollPEG-DSPE (89:5:6, S-SL)
and soybean lecithinlChol (95:5, S-CL). Liposomes composed with DSPC or
soybean lecithin are indicated with D or S, .respectively. PEGylated liposomes
and non-PEGylated liposomes are indicated as SL and CL, respectively.
Therefore, D-SL indicates PEGylated liposomes composed of DSPC and Chol
(Table 5). Liposomal everolimus was prepared by an ethanol injection
method.(8i) Briefly, all lipids (20 mg) and everolimus were dissolved in
ethanol (2 ml). This alcoholic solution was added into distilled water (4 ml)
immediately, followed by sonication to decrease the size of liposomes to
approximate 100 nm. The residual ethanol was removed by evaporation under
reduced pressure. The resulting mean diameter ofthe liposomes was measured
by dynamic light scattering (ELS-Z2, Otsuka Electronics, Osaka, Japan) at
250C after diluting the liposome suspension with water. The entrapment
efficiency of everolimus was calculated by separating un-encapsulated from
encapsulated drug by gel filtration chromatography using a Sephadex G50
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column. The everolimus concentration was measured with the use of an HPLC
system (Shimadzu Co., Kyoto, Japan) composed of an LC-20AT pump, an
SIL-20A autoinjector and an SPD-M20A detector measuring absorbance of
278 nm, using a TSKgelODS-80Ts QA 5 mm column (4.6 mm I.D. x 250 mm,
TOSHO, Co., Ltd., Tokyo, Japan). The mobile phase was 200/o methanol at a
flow rate of 1 mllmin. Under these conditions, everolimus was eluted at 10.1
min. The everolimus concentration of each sample was determined using a
calibration curve. The everolimus-to-lipid molar ratio was O.02, as referenced
from a previous report,(79) and the final lipid concentration was
approximately 1 mglml.
2.4. Cytotoxicity assay
      Cells were seeded into 96-well plates at a density of 104 cellslwell for
24 h before addition of the drug. Culture medium was replaced with fresh
medium, containing various concentrations of free everolimus. After 48 h
incubation with free and liposomal everolimus at 370C, the cells were washed
with PBS three times. Then, cell viability was determined using a WST-8 test
(Dojindo Laboratories, Kumamoto, Japan). All measurements were carried
out in quadruplicate. IC50 was calculated using the bootstrap method.(54)
      To evaluate co--treatment cytotoxicity of free everolimus and CPT-11
on these cells, cells were incubated with 10-100 nM everolimus in the
absence or presence of 1.5 pM CPT- 11 for 48 h at 370C.(82) Cell viability was
determined as described above.
2.5. Animal experiments
      All animal experiments were performed with approval from the
Institutional Animal Care and Use Committee at Hoshi University. NCI-H446
cells (1 Å~ 107) were inoculated subcutaneously into female BALBIc nulnu
mice (6 weeks of age, CLEA Japan, Inc., Tokyo, Japan). When the average tumor
volume was approximately 100 mm3, free everolimus was administrated intraperitoneally
at a dose of 1 mg or 5 mg/kg, in five injections at five-day intervals. Free everolimus was
unable to be injected intravenously because of low solubility in water.
Therefore, everolimus solution in mixture of 50/o polyethylene glycol and 50/o
Tween-80, was intraperitoneally injected. D-SL was administrated
intravenously equivalent to 5 mg everolimuslkg. Tumor volume and body
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weight were measured as described in Experimental
2.6. Statistical analysis
      It was described in 2.10 of Chapter 2.
section of Chapter 2
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3. Results
3.1. Size and zeta-potential of liposomes
      Table 5 presents the particle size and everolimus entrapment
efficiency of liposomal formulations. The results indicated that all liposome
sizes were -80 nm with a polydispersity less than O.19. Entrapment efficacies
of everolimus were very different between D-CL and S-CL. S-CL showed
95.70/o entrapment efficiency, but the value for D-CL was 6.50/o. Meanwhile,
D-SL, PEGylated D-CL, showed an 88.40/o entrapment efficiency. Therefore,
liposomal everolimus in the forms of D-SL, S-SL and S-CL were used in the
following experiment.
Table 5. Characteristic of liposomal everolimus
Formulation Abbr. Size (nm) Polydispersity Entrapment
efficacy (Olo)
DSPC/Chol/PEG-DSPE
DSPC/Chol
Soybean lecithin
/Chol/PEG-DSPE
Soybean lecithin /Chol
D-SL
D-CL
S-SL
S-CL
76.1 Å} 2.0
91.4 Å} 23.9
68.0 Å} 5.5
77.9 Å} 3.3
O.178 Å} O.O17
O.169 Å} O.029
O.161 Å} O.045
O.188 Å} O.O13
88.4 Å} 4.3
 6.5 Å} 1.5
92.7 Å} 5.7
95.7 Å} 2.0
Note; Mean Å} S.D. (n = 3).
3.2. Antitumor effect of Iiposomal everolimus in vitro
      I chose three tumor cell lines to evaluate the cytotoxicity of free and
liposomal everolimus. In MCF-7 cells and NCI-H446 cells, the
PI3KIAktlmTORIp70S6K pathway was reported to be active, and mTOR
pathway inhibition showed anticancer effects in an in vitro study.(83' 84) McF-7
cells and NCI-H446 cells were used as positive controls. TT cells were used to evaluate
the cytotoxicity of octreotide-modified liposomes in Chapters 1 and 2.(66• 85)
The IC50 values of free everolimus in NCI-H446 cells, TT cells and MCF-7
cells were 73.1 Å} 25.3 nM, 153.4 Å} 12.2 nM and more than 260 nM,
respectively (Table 6). This finding indicated that the sensitivity of
cytotoxicity of everolimus in these tumor cells was higher in this order;
NCI-H446 År TT År MCF-7. Therefore, I selected NCI-H446 and TT cells for
further experiments.
                              51
Table 6. Cytotoxicity of free everolimus
NCI-H446
rr
MCF-7
73.1 Å} 25.3
153.4 Å} 12.2
   År 260
Note; Mean Å} S.D. (n = 4).
      Next, I examined the cytotoxicity of liposomal everolimus. As shown
in Fig. 22, the IC50 of all liposomal everolimus formulations except for D-SL
in NCI-H446 cells were over 260 nM after 48 h incubation, indicating that the
cytotoxicity in liposomal everolimus was reduced compared with free
everolimus. In liposomal everolimus, D-SL showed the highest cytotoxicity
for both cell types, suggested that release of the drug from D-SL might occur
during the 48 h incubation. From Table 6 and Fig. 22, I estimated that
everolimus in D-SL may be kept in liposomal lipid outer membrane by
PEG-lipid and may be released more easily than in S-CL or S-SL. Therefore, I
selected D-SL for in vivo experiments.
3.3. Antitumor effect on NCI-H446 tumor xenografts
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Figure 22. Cytotoxicity of liposomal everolimus in TT cells (A)
or NCI-H446 cells (B)
Cells were incubated with liposomal everolimus at various concentrations
for 48 h.
Each value represents the mean Å} S.D. (n==4).
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      The antitumor activity of free and liposomal everolimus was evaluated
after five injections as five-day intervals into NCI-H446 tumor xenografts.
Tumor inoculation day was defined as day O. As shown in Fig. 23A, one
mglkg-treated mice did not get significant tumor suppression compared with
saline-treated mice by day 70. Free everolimus- or D-SL-treated mice, at a
dose of 5 mglkg, showed tumor suppression, compared with saline at day 39
to day 59 (P Åq O.05). Body weight loss was not observed in any of the
treatment groups (Fig. 23B).
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Figure 23. Effect of free and liposomal everolimus on antitumor
activity (A) and body weight change (B) in mice bearing
NCI-H446 tumors
Antitumor activity and toxicity were assessed by measuring tumor volume
and body weight change after intraperitoneal injections of free everolimus
and after intravenous injections of D-SL (equivalent to 5 mg
everolimuslkg). D-SL (o), free 5 mg (A), free 1 mg everolimuslkg (o) or
saline (e) were administrated on days 24, 29, 34, 39 and 44 days after
inoculation, as shown by arrows.
Each value represents the mean Å} S.D. (n = 6).
", Statistically significant differences between free 5 mg everolimuslkg and
D-SL (P Åq O.05).
53
3.4. Ce-treatment efficacy with everolimus and CPT-11 in vitro
      Everolimus was reported to have synergistic cytotoxicity in
combination with other chemotherapeutic agents on several cancer cell types.
(8i'83) Moreover, I described that mTOR pathway inhibition by
octreotide-modified liposome without drug loading enhanced cell
cytotoxicity in the presence or absence of CPT-11 in TT cells in Chapter 2.
Everolimus is an mTOR inhibitor, and octreotide-modified liposomes
functioned as an mTOR inhibitor. Therefore, I compared the cytotoxicity of a
combination of CPT-11 and everolimus with that of CPT-11 and
octreotide-modified liposomes. Similar to my result in Chapter 2 of
co-treatment of 1.5 pM CPT-11 and octreotjde-modified liposomes, the
cytotoxicity of everolimus in the absence or presence of CPT-11 increased in
a dose-dependent manner for everolimus in all treatments of NCI-H446 cells
(Fig. 24).
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Figure 24. Co-treatment effects of free everolimus in the
absence or presence of free CPT-11 on cell viability in TT cells (A)
or NCI-H446 cells (B)
Cells were treated with 10-100 nM everolimus in the presence or absence of 1.5 ptM
9PT-11 for 48 h. The data represent the means Å} S.D. (n = 4).
 , Statistically significant differences between "control" (no treatment) and
everolimus treatment (P Åq O.05).
#, Statistically significant differences between CPT-11 alone and
co-treatment with everolimus and CPT-11 (P Åq O.05).
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4. Discussion
      In this Chapter, I prepared liposomal everolimus and demonstrated
that a significant therapeutic efficacy with the liposomes in vitro and in vivo.
      Regarding entrapment efficiency of liposomal everolimus, S-CL
showed high entrapment efficiency, but the value for D-CL was low. This
result for S-CL agreed with a previous report.(79) Soybean lecithin is
composed of mainly linoleic acid (62-650/o) with a double bond. Therefore I
estimated that everolimus might interact with the double bond of linoleic
acid.
      Meanwhile, D-SL, PEGylated D-CL, showed more than 800/o
entrapment efficiency. With the increase in the PEG-DSPE ratio in the
liposome composition, the entrapment efficiency of everolimus increased
(data not shown). Thus, in the case of the liposomes consisting of DSPC,
PEG-lipid may assist the entrapment of everolimus into the liposome
membrane.
      In therapeutic study in NCI-H446 xenografts, significant antitumor
efficacy was observed. In a comparison with the free everolimus-treatment
group, the liposomal everolimus-treatment group without body weight losses
at a dose of5 mglkg showed significant tumor suppression at day 49 to day 59
(P Åq O.05), which reflected the prolongation of drug activity with the use of a
liposomal formulation. To the best ofour knowledge, this is the first report of
the anti-tumor efficacy of liposomal everolimus in an in vivo experiment. It
was reported that one ofthe features ofrapalog is lifespan extension.(86) with
regard to the survival, two saline-treated mice died during 97 days period of
the study, and both had large tumors (approximately 105 mm3) (data not
shown). Although free or liposomal everolimus-treated mice also bore
large-tumors, all of the mice were alive at the end of the 97 day study period.
Median survival for mice treated with saline was 125.5 days, compared with
136 days for 1 mg everolimus-treated, 137 days for 5 mg everolimus-treated,
and 146 days for D-SL (5 mg everolimuslkg)-treated mice. The O/olLS value of
1 mg everolimuslkg-treated, 5 mg everolimuslkg-treated and D-SL (5 mg
everolimus/kg)-treated mice was 8.4, 9.2 and 16.3, respectively. There is a
significant difference tendency between the survival time of D-SL-treated
mice and that of saline-treated mice (P = O.055 by log-rank test). In this study,
lifespan was also evaluated to be increased in liposomal everolimus.
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      Moreover, mTOR inhibition effect in NCI-H446 cells by everolimus
showed significant antitumor effects in the presence and absence of CPT-11,
at everolimus dose-dependent manner. Therefore, in the future, if the dose of
everolimus and CPT-11 in combination therapy was optimized, efficient
therapeutic efficacy should be achieved in an in vivo experiment.
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5. Conclusion
      In conclusion, I was able to prepare liposomal everolimus and
succeeded the TT tumor cell growth-suppression in vitro, and the NCI-H446
tumor-suppression in vitro and in vivo, using this formulation of mTOR
inhibitor.
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SUMMARY
      Developing new approaches toward rare cancers are very important
from a social and medical viewpoint. Furthermore, efforts to generate
therapies for rare cancers might clarify new viewpoints and provide insight
into the treatment of common cancers. MTC, one of the rare cancers has been
lacking in effective therapeutic treatment except for surgery. In animal study,
therapeutic efficacy for MTC using CPT-11 has been r,eported. However, the
approach was fail as consequence of serious side effects. To increase the
therapeutic efficacy of MTC with CPT- 11, it is necessary of active-targeting,
selective delivery of drug to tumor sites. For this purpose, particulate drug
carriers are useful. Especially, particle surface modification with tumor
targeting ligand is a promising method to high therapeutic efficacy. However,
when targeting moieties are employed to liposomes, their circulation times
are often decreased in vivo, owing to recognition by the RES. Thus, it is
difficult to generate active targeting liposomes for cancer therapy.
      In this thesis, Oct-targeted liposomes loaded with CPT-11 were
prepared, evaluated and compared with free CPT-11, non-PEGylated
liposomes and PEGylated non-targeted liposomes for MTC therapy. Moreover,
the functions of Oct ligand were clarified.
      In Chapter 1, it was demonstrated that Oct-targeted liposomes loaded
with CPT-11 associated selectively with TT cells via somatostatin receptor.
Optimal Oct-modification of liposomes for cellular uptake was more than
1.4molO/o. Thus, 1.6molO/o Oct-targeted liposomes loaded with CPT-11 may be
able to offer a high therapeutic potential for MTC. In addition, it was
observed that 200/o cell death in TT cells was caused by 100 pM free Oct and
O.42 pM Oct ligand. Thus, I found that empty Oct-targeted liposomes
exhibited 238-fold higher cytotoxicity than free Oct in TT cells.
      In Chapter 2, Oct-targeted liposome exhibited MTC therapeutic
efficacy in vivo: strong antitumor effects and the lifespan-expansion,
compared with free CPT-11, non-PEGylated liposomes and PEGylated
liposomes. Moreover, from the results of the biodistribution and
bioconversion of Oct-targeted liposomes, it was demonstrated that Oct
ligands delivered selectively the liposomes to tumor sites, and the released
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CPT-11 in tumor may be converted into active metabolite, SN-38. From
Chapters 1 and 2, it was clarified that Oct-targeted liposomes loaded with
CPT-11 are effective for MTC therapy, due to the selective delivery of drug
and the assistance of cell growth suppression by Oct-ligand. Oct-ligand,
empty Oct-targeted liposomes, inhibited PI3KIAktlmTOR pathway. However,
empty Oct-targeted liposomes did not show antitumor effect in vivo,
suggesting that contributing to prolong the time to tumor progression. Thus, I
examined antitumor effect of mTOR inhibitors in vivo as an active control.
      In many cancer cells including MTC cells, lung cancer cells, and
breast cancer cells and so on, PI3KIAktlmTOR pathway is activated to cell
growth and cell proliferation. Everolimus was selected as a model drug of an
mTOR inhibitor. In Chapter 3, liposomal everolimus was prepared to evaluate
the antitumor effect of an mTOR inhibitor in MTC cells and lung cancer cells.
The liposome formulation of everolimus was able to suppress the tumor
growth of both cells. Therefore, liposomal mTOR inhibitor affords the
possibility of different formulations to treat MTC.
      In conclusion, active targeting, Oct-targeted liposomes loaded with
CPT-11 will be useful for treatment of MTC. Oct-targeted liposomes
exhibited that Oct ligand is effectively recognized by somatostatin receptors
and acts tumor cell growth suppression via mTOR inhibition more than free
Oct. Oct-•targeted liposomes will be one of effective formulations for Oct,
single drug when binding with somatostatin receptors andlor high
concentration in targeted cells are needed. Furthermore, in dual-targeted
approach therapy with Oct, Oct-targeted liposomes will provide one particle
formulation if another drug can be loaded in the same particles. Oct-targeted
particles may give further opportunities to treatments of not only MTC, rare
cancers, but also somatostatin receptor positive- and PI3KIAktlmTOR
pathway activated-tumors, such as lung carcinoma, common cancers.
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